Recent

% | $
Quotes you view appear here for quick access.

Trius Therapeutics, AŞ Message Board

  • beavertail_splash beavertail_splash Jun 10, 2013 10:40 AM Flag

    Gram Negative fluoroquinolone antibacterial agents

    ...any ideas on updates regarding the GyrB/ParE clinical trials expected to start next year?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • TSRX's PIPELINE POTENTIAL
      "Through funding under a contract with the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health, our preclinical program targeting GyrB/ParE is focused on identifying and developing novel antibiotics to treat serious infections caused by gram-negative bacterial pathogens.
      Our second preclinical program, the MurB program, is funded by a three year contract from the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense. In this program, we are working with Lawrence Livermore National Laboratories to discover novel antibacterial agents that target MurB, an essential bacterial cell wall enzyme"
      Closing in on initiating phase 1 clinical studies on GyrB/ParE
      This will be bigger than Tedizolid.

      • 2 Replies to beavertail_splash
      • The best information you're going to find is from the ICAAC posters.

        There is a poster from the 2012 ICAAC titled "Antibacterial Agents Targeting DNA Gyrase B and Topoisomerase IV: Discovery of a New Class by Structure-Based Drug Design". They have some interesting compounds, you can look through the relative activities in the results section.

      • "The alarming increase in drug resistant Gram-negative infections underscores the need for
        therapeutic agents that work via novel mechanisms of action. Bacterial DNA Gyrase B (GyrB) and
        topoisomerase IV (ParE) are validated antibacterial targets. This target pair has been utilized in the past, but the antibacterial spectrum of resulting compounds has been mainly limited to Gram-positive bacteria. The aim of this program is to expand spectrum to include important Gram-negative pathogens."